MONDAY, Nov. 23, 2020 -- Due to disproportionate representation, Black and Hispanic patients bear much of the burden of mortality and morbidity related to COVID-19, according to a study published online Nov. 17 in Circulation to coincide with the American Heart Association Scientific Sessions 2020, held virtually from Nov. 13 to 17.
Fatima Rodriguez, M.D., M.P.H., from Stanford University in California, and colleagues examined racial/ethnic differences in presentation and outcomes for patients hospitalized with COVID-19. Data from the American Heart Association COVID-19 Cardiovascular Disease Registry were presented for the first 7,868 patients treated at 88 U.S. hospitals between Jan. 17 and July 22, 2020.
The researchers found that 33.0, 25.5, 6.3, and 35.2 percent of patients hospitalized with COVID-19 were Hispanic, non-Hispanic Black, Asian, and non-Hispanic White, respectively. The highest prevalence of obesity, hypertension, and diabetes was seen in Black patients. In addition, the highest rates of mechanical ventilation (23.2 percent) and renal replacement therapy (6.6 percent) occurred among Black patients, and they had the lowest rates of remdesivir use (6.1 percent). Overall mortality was 18.4 percent; more than half (53 percent) of all deaths occurred in Black and Hispanic patients. Compared with non-Hispanic Whites, the adjusted odds ratios for mortality were 0.93 (95 percent confidence interval, 0.76 to 1.14), 0.90 (95 percent confidence interval, 0.73 to 1.11), and 1.31 (95 percent confidence interval, 0.96 to 1.80) for Black, Hispanic, and Asian patients, respectively. Results were similar for major adverse cardiovascular events.
"The COVID-19 pandemic has shown a spotlight on racial and ethnic disparities in health care that have been happening for years," Rodriguez said in a statement.
Abstract/Full Text (subscription or payment may be required)
© 2020 HealthDay. All rights reserved.
Posted: November 2020
MONDAY, Nov. 23, 2020 -- On Monday, AstraZeneca announced that late-stage clinical trials of its COVID-19 vaccine showed it to be 70.4 percent effective, The New York Times...
MONDAY, Nov. 23, 2020 -- The use of remdesivir currently is not recommended for hospitalized COVID-19 patients because of the lack of evidence for improvement in mortality, need...
MONDAY, Nov. 23, 2020 -- The novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, is well tolerated, especially among older adults, according to a study published online...
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.